DBD is expected to report earnings to rise 44.55% to $1.59 per share on November 05
Q3'26
Est.
$1.59
Q2'26
Missed
by $0.13
Q1'26
Beat
by $0.05
Q4'25
Beat
by $1.30
Q3'25
Beat
by $0.28
The last earnings report on July 29 showed earnings per share of $1.10, missing the estimate of $1.23. With 227.49K shares outstanding, the current market capitalization sits at 2.45B.
Nuveen Massachusetts Quality Municipal Income Fund
DBD and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, DBD has been loosely correlated with GDRX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if DBD jumps, then GDRX could also see price increases.
DBD in downward trend: price dove below 50-day moving average on July 29, 2026
DBD moved below its 50-day moving average on July 29, 2026 date and that indicates a change from an upward trend to a downward trend. In of 34 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for DBD turned negative on July 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 29 similar instances when the indicator turned negative. In of the 29 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for DBD crossed bearishly below the 50-day moving average on August 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DBD's RSI Indicator exited the oversold zone, of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on August 13, 2026. You may want to consider a long position or call options on DBD as a result. In of 51 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DBD advanced for three days, in of 211 cases, the price rose further within the following month. The odds of a continued upward trend are .
DBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 168 cases where DBD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.530) is normal, around the industry mean (28.717). P/E Ratio (23.921) is within average values for comparable stocks, (82.489). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.745). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.674) is also within normal values, averaging (77.023).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. DBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
